DxTerity Diagnostics | GenomeWeb

DxTerity Diagnostics

The firm plans to seek Emergency Use Authorization for the 18-gene panel and will subsequently submit it to the FDA for full approval.

The firm will use the money from SWK Funding to commercialize its DxDirect genomic testing platform and its DxCollect MicroCollection Device.

The additional funds bring the total contract to $43 million over approximately eight years.

With eight independently programmable amplification wells, the firm's portable PCR platform is now in small-scale production.

Molecular diagnostics company DxTerity Diagnostics was recently awarded a $280,000 Small Business Innovation Research contract from the National Cancer Institute to develop a test for susceptibility to radiation sickness during cancer treatment.

DxTerity Diagnostics has developed a rapid assay for analyzing gene expression of as many as 100 genes directly from small amounts of formalin-fixed, paraffin-embedded clinical samples without prior RNA extraction.

DxTerity plans to make the gene expression assays functional with its Non-Enzymatic Amplification Technology platform.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.

Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.

Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.

British researchers say they've been removed from EU grant applications, according to the Guardian.